Swiss National Bank Lowers Stock Holdings in Charles River Laboratories International, Inc. $CRL

Swiss National Bank lowered its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 5.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 93,800 shares of the medical research company’s stock after selling 5,300 shares during the period. Swiss National Bank owned about 0.19% of Charles River Laboratories International worth $14,232,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Exchange Traded Concepts LLC lifted its position in Charles River Laboratories International by 1.3% in the 2nd quarter. Exchange Traded Concepts LLC now owns 5,742 shares of the medical research company’s stock worth $871,000 after buying an additional 76 shares during the last quarter. Brooklyn Investment Group raised its stake in shares of Charles River Laboratories International by 93.5% during the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after acquiring an additional 86 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in shares of Charles River Laboratories International by 1.2% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,142 shares of the medical research company’s stock worth $1,072,000 after acquiring an additional 86 shares during the last quarter. WESCAP Management Group Inc. boosted its stake in shares of Charles River Laboratories International by 3.8% in the 2nd quarter. WESCAP Management Group Inc. now owns 2,443 shares of the medical research company’s stock valued at $371,000 after purchasing an additional 89 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D grew its holdings in shares of Charles River Laboratories International by 0.7% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 16,829 shares of the medical research company’s stock valued at $2,553,000 after purchasing an additional 109 shares during the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CRL. Weiss Ratings reissued a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, October 8th. Baird R W upgraded Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 6th. Mizuho boosted their target price on Charles River Laboratories International from $155.00 to $174.00 and gave the company a “neutral” rating in a research note on Friday, October 17th. Wall Street Zen lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Robert W. Baird upgraded Charles River Laboratories International from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $178.00 to $199.00 in a research report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Moderate Buy” and an average price target of $190.86.

Charles River Laboratories International Stock Up 0.4%

NYSE CRL opened at $178.76 on Friday. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $203.01. The stock has a market capitalization of $8.80 billion, a PE ratio of -134.41, a PEG ratio of 4.83 and a beta of 1.53. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. The business’s 50-day moving average is $171.23 and its 200 day moving average is $159.80.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The business had revenue of $1 billion during the quarter, compared to analyst estimates of $990.43 million. During the same quarter in the prior year, the company posted $2.59 EPS. Charles River Laboratories International’s quarterly revenue was down .5% compared to the same quarter last year. Sell-side analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).